Kalaris Therapeutics, Inc. (KLRS)
NASDAQ · Healthcare
$4.00-8.68%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $81.92M
- P/E ratio
- —
- EPS
- —
- Volume
- 492,875
- 52-week high
- —
- 52-week low
- —
- Open
- $4.25
- Day high
- $4.59
- Day low
- $3.95
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | — | -$43.44M | -$2.85 |
| 2024 | — | -$69.17M | -$51.77 |
| 2023 | — | -$190.42M | -$42.09 |
| 2022 | — | -$168.71M | -$2.20 |
| 2021 | — | -$171.96M | -$2.74 |
About Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
- CEO
- Andrew Oxtoby
- Employees
- 20
- Country
- US
- IPO date
- Jul 30, 2020
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Kalaris Therapeutics, Inc.'s stock price today?
- KLRS is trading at $4.00 as of Jul 20, 2026.
- What is Kalaris Therapeutics, Inc.'s market cap?
- Kalaris Therapeutics, Inc. (KLRS) has a market capitalization of $81.92M.
- Does Kalaris Therapeutics, Inc. pay a dividend?
- Kalaris Therapeutics, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Kalaris Therapeutics, Inc. in?
- Kalaris Therapeutics, Inc. operates in the Healthcare sector.